Verrica Pharmaceuticals Inc. is an innovative dermatology therapeutics company committed to identifying, developing, and commercializing novel pharmaceutical products for the treatment of skin diseases and conditions with significant unmet needs. They seek to understand the patient journey and the healthcare provider landscape when developing clinical programs, with the goal of delivering treatment solutions for millions of underserved patients.
Lead product candidate, VP-102, is a proprietary drug-device combination of a novel topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, clinically administered through a single-use precision applicator. Initially developing VP-102 for the treatment of molluscum contagiosum, a highly contagious and primarily pediatric viral skin disease, and common warts.
US - Middle Atlantic
Marketed, Phase III, Phase l or ll
100MM - 500MM
10 North High Street
West Chester, PA 19380
Top 10 Holders of Verrica Pharmaceuticals Inc
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by